Amarin to Present at Piper Sandler’s 32nd Annual Healthcare Conference (Virtual)
Amarin Corporation plc (NASDAQ:AMRN) announced that CEO John F. Thero will participate in a Fireside Chat at the Piper Sandler’s 32nd Annual Healthcare Conference from December 1-3, 2020. Thero's presentation is set for December 2, 2020, at 10:00 AM ET. A live audio webcast of the session will be available on Amarin's website and accessible for 30 days. Amarin focuses on developing therapeutics to improve cardiovascular health, with its lead product, VASCEPA® (icosapent ethyl), approved in select countries.
- None.
- None.
DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer, is scheduled to participate in a Fireside Chat at the Piper Sandler’s 32nd Annual Healthcare Conference (Virtual) taking place from December 1 - December 3, 2020. Mr. Thero’s presentation is scheduled to take place on Wednesday, December 2, 2020 at 10:00 am Eastern time.
A live audio webcast of the presentations will be available at: http://www.amarincorp.com, and will be accessible at the same link for 30 days.
About Amarin
Amarin Corporation plc is a rapidly growing, innovative pharmaceutical company focused on developing and commercializing therapeutics to cost-effectively improve cardiovascular health. Amarin’s lead product, VASCEPA® (icosapent ethyl), is available by prescription in the United States, Canada, Lebanon and the United Arab Emirates. VASCEPA is not yet approved and available in any other countries. Amarin, on its own or together with its commercial partners in select geographies, is pursuing additional regulatory approvals for VASCEPA in China, Europe and the Middle East. For more information about Amarin, visit www.amarincorp.com.
Availability of Other Information About Amarin
Investors and others should note that Amarin communicates with its investors and the public using the company website (http://www.amarincorp.com/), the investor relations website (http://investor.amarincorp.com/), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media, and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Amarin Contact Information
Investor Inquiries:
Investor Relations
Amarin Corporation plc
In U.S.: +1 (908) 719-1315
IR@amarincorp.com (investor inquiries)
Solebury Trout
amarinir@troutgroup.com
Media Inquiries:
Communications
Amarin Corporation plc
In U.S.: +1 (908) 892-2028
PR@amarincorp.com (media inquiries)
FAQ
What event is Amarin Corporation participating in on December 1-3, 2020?
When is John F. Thero's presentation scheduled during the Piper Sandler Conference?
Where can I watch the live audio webcast of Amarin's conference presentation?
What is VASCEPA, Amarin's lead product?
In which countries is VASCEPA currently approved?
